Skip to content
OpenCapital
Get started

IDEAYA Biosciences, Inc. IDYA Research And Development Services — Revenue Remaining Performance Obligation

Similar metrics at other companies

Nuvation Bio logo
NUVBResearch And Development Service Revenue — Deferred Revenue
$18.4M+9,100%
Nuvation Bio logo
NUVBResearch And Development Service Revenue — Contract With Customer Liability Revenue Recognized
$8.6M+359%
BioCryst Pharmaceuticals logo
BCRXResearch and Development — Contract with customer, transaction price
$20.67M—
BridgeBio Pharma logo
BBIOResearch and Development Services — Deferred revenue, net of current portion
$1.9M—
Blackrock logo
BLKTechnology Services And Subscription Revenue — Revenue Remaining Performance Obligation
$509M+6.0%
Berkshire Hathaway logo
BRK.AOther Sales And Service Contracts — Revenue Remaining Performance Obligation
$14.48B+80.9%

Other financials

Income statement

See full
Revenue$6.6M—
Operating income-$108.5M-28.6%
Net income-$98.5M-36.5%
EPS (diluted)-$1.11-35.4%

Balance sheet

See full
Cash & equivalents$157.5M+21.2%
Total debt$28.6M+10.1%
Total equity$937.3M-8.5%
Total assets$1.0B-6.4%

Cash flow

See full
Operating cash flow-$75.2M-24.6%
CapEx$967.0K-27.3%
Free cash flow-$76.1M-23.5%

Valuation

See full
Market cap$3.36B+104%
Enterprise value$3.23B+110%
P/S14.5×+9.9×

Profitability

See full
Operating margin-4,671.1%-5,434pp
Net margin-3,921.1%-4,562pp
FCF margin-3,592%-4,290pp

Returns & leverage

See full
Return on equity-14.3%-5.0pp
Debt / equity0×0.0×
Current ratio10.7×-3.2×

Where this comes from

Reported directly by IDEAYA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueRemainingPerformanceObligation.

The official record: IDEAYA Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about IDEAYA Biosciences, Inc.'s research and development services — revenue remaining performance obligation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is IDEAYA Biosciences, Inc.'s research and development services — revenue remaining performance obligation?
IDEAYA Biosciences, Inc. (IDYA) reported research and development services — revenue remaining performance obligation of $155.3M in Q1 2026.
What does research and development services — revenue remaining performance obligation mean?
This metric represents the total transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied for research and development service contracts. It reflects the aggregate amount of future revenue that the company expects to recognize as it fulfills its contractual obligations to partners in precision medicine development. This figure serves as a key indicator of the company's contracted revenue backlog and the long-term visibility of its collaborative research pipeline.